| Published Documents & News ReleasesNovember 1, 2007
Seaport World Trade Center
Boston, Massachusetts
Drawing on dialogue initiated among leaders in the field at a highly successful planning workshop sponsored by the iSBTc in 2006, this in-depth program provided an assessment of state-of the-art opportunities for combining immune-stimulating agents with other cancer biologics as well as conventional antineoplastic agents. This highly interactive program provided a venue for intensive scientific dialogue among key stakeholders regarding both strategic opportunities and central obstacles to realizing the potential of combination approaches for the biological therapy of cancer. It is anticipated that participants in this important program will include broad representation by investigators from academia, industry and regulatory agencies in the U.S., Europe and beyond.
| Bernard A. Fox, PhD Earle A. Chiles Research Institute |
Thomas F. Gajewski, MD, PhD University of Chicago |
| Rachel W. Humphrey, MD Bristol-Myers Squibb Company |
Hyam I. Levitsky, MD Johns Hopkins University School of Medicine |
| Jon M. Wigginton, MD Merck & Co., Inc. |
|
